Bladder cancer has the highest recurrence rate of any solid tumor. Due to the need for life-long surveillance, the perpatient cost of managing bladder cancer is among the highest for any cancer. In the context of relative limitations of the current standard of cystoscopy and cytology, there has been growing activity in the development of novel markers for bladder cancer detection. The ultimate goal of these novel markers would be to replace and/or complement cystoscopy as a sensitive and noninvasive surveillance tool. Standard prognostic features have limited ability to predict the outcome for bladder cancer patients. With recent advances in techniques, an extremely large number of new markers have been identified. New biomarkers that are predictive of outcomes would help clinicians provide the risk-stratification of patients and serve as prognostic indicators for individual patients.

Continuing identification of new markers in bladder cancer will enhance future diagnostic and therapeutic approaches to bladder cancer. We invite investigators to contribute original research articles as well as review articles that will stimulate continuing efforts to leverage biomarkers to improve diagnostic accuracy, discover the molecular pathophysiology underlying bladder cancer, develop strategies to treat these conditions, and evaluate the prognosis.

Potential topics include, but are not limited to:

• Recent developments of diagnostic and prognostic biomarkers in bladder cancer
• Advanced researches in diagnosis and surveillance of bladder cancer
• The latest technologies for clinical evaluation and measuring outcomes with biomarkers